Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Commentary|Videos|February 18, 2026
Examining the Key Design Characteristics of the Bionic Breast Program
Author(s)Stacy Tessler Lindau, MD, MA
Fact checked by: Kyle Doherty
Stacy Tessler Lindau, MD, MA, discusses the design of the Bionic Breast project at University of Chicago.
Advertisement
Stacy Tessler Lindau, MD, MA, outlines the multifaceted design of the Bionic Breast project. Bionic Breast is a portfolio of research that includes an NIH- and NCI-funded trial that aims to enroll 8 patients over the course of 5 years. Eligible patients are women undergoing bilateral mastectomy to treat or prevent cancer at the University of Chicago. Patients will serve as their own controls in the study; one breast will receive a neuroprosthetic implant, and the other will not.
Advertisement
Related to this article
Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.
Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
Advertisement
Advertisement
Trending on OncLive
1
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
2
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
3
Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma
4
European Commission Approves Camizestrant Plus CDK4/6 Inhibition for Emergent ESR1-Mutated Advanced Breast Cancer
5